• Patient, parent, or legal guardian must have given written informed consent.

• Patient must be 2 months to 60 years (inclusive) of age at time of consent for all diagnoses.

• Patients should have a non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to the following:

• A. Primary Immunodeficiency Syndromes

⁃ Severe Combined Immune Deficiency (SCID) with NK cell activity

⁃ Omenn Syndrome

⁃ Bare Lymphocyte Syndrome (BLS)

⁃ Combined Immune Deficiency (CID) syndromes

⁃ Combined Variable Immune Deficiency (CVID) syndrome

⁃ Wiskott-Aldrich Syndrome

⁃ Leukocyte adhesion deficiency

⁃ Chronic granulomatous disease (CGD)

⁃ Hyper IgM (XHIM) syndrome

⁃ IPEX syndrome

⁃ Chediak-Higashi Syndrome

⁃ Autoimmune Lymphoproliferative Syndrome (ALPS)

⁃ Hemophagocytic Lymphohistiocytosis (HLH) syndromes

⁃ Lymphocyte Signaling defects

• B. Congenital Bone Marrow Failure Syndromes

⁃ Congenital Amegakaryocytic Thrombocytopenia (CAMT)

⁃ Osteopetrosis

• C. Inherited Metabolic Disorders (IMD)

⁃ Mucopolysaccharidoses

∙ Hurler syndrome (MPS I)

‣ Hunter syndrome (MPS II)

⁃ Leukodystrophies

∙ Krabbe Disease, also known as globoid cell leukodystrophy

‣ Metachromatic leukodystrophy (MLD)

‣ X-linked adrenoleukodystrophy (ALD)

⁃ Other inherited metabolic disorders

∙ Alpha Mannosidosis

‣ Gaucher Disease

‣ Other inheritable metabolic diseases where HSCT may be beneficial

• D. Hereditary Anemias

⁃ Thalassemia major

⁃ Sickle cell disease (SCD)

⁃ Diamond Blackfan Anemia (DBA)

• E. Inflammatory Conditions

⁃ Crohn's Disease or Inflammatory Bowel Disease

⁃ IPEX or IPEX-like Syndromes

⁃ Rheumatoid Arthritis

⁃ Other inflammatory conditions where HSCT may be beneficial

• Subjects receive either umbilical cord blood, bone marrow, or peripheral blood stem cell transplant with an alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen, according to clinical practice at UPMC Children's Hospital of Pittsburgh.